How to manage the infectious risk under anti-TNF in inflammatory bowel disease

Current Drug Targets

Volumn 11, Issue 2, 2010, Pages 198-218

  Culver, Emma L ^a   Travis, Simon P L ^a  

^a JOHN RADCLIFFE HOSPITAL   (United Kingdom)

Author keywords

Adalimumab; Complications; Crohn's disease; Infliximab; Opportunistic infections; Review; Risk management; Ulcerative colitis

Indexed keywords

ADALIMUMAB; AZATHIOPRINE; CORTICOSTEROID; IMMUNOMODULATING AGENT; INFLIXIMAB; ISONIAZID; METHOTREXATE; TUMOR NECROSIS FACTOR ANTIBODY;

ASPERGILLUS; BACTERIAL INFECTION; CANDIDA; CHEMOPROPHYLAXIS; CLINICAL PRACTICE; CLOSTRIDIUM DIFFICILE; CRYPTOCOCCUS NEOFORMANS; CYTOMEGALOVIRUS; ENTERITIS; EPSTEIN BARR VIRUS; HEPATITIS B; HEPATITIS C; HERPES SIMPLEX VIRUS; HISTOPLASMA CAPSULATUM; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; IMMUNE RESPONSE; IN VITRO STUDY; IN VIVO STUDY; INFECTION; INFLUENZA; INFLUENZA VIRUS A H1N1; JC VIRUS; LEGIONELLA PNEUMOPHILA; LISTERIA MONOCYTOGENES; LONG TERM CARE; MALNUTRITION; MYCOSIS; NOCARDIA; OPPORTUNISTIC INFECTION; PARASITOSIS; PATIENT EDUCATION; PNEUMOCYSTIS JIROVECI; PREVALENCE; REVIEW; RISK FACTOR; SALMONELLA; STREPTOCOCCUS PNEUMONIAE; STRONGYLOIDES STERCORALIS; TOXOPLASMA GONDII; TRAVEL; TUBERCULOSIS; VACCINATION; VARICELLA ZOSTER VIRUS; WART VIRUS;

ANIMALS; ANTI-INFLAMMATORY AGENTS; DRUG MONITORING; GLUCOCORTICOIDS; HUMANS; IMMUNOSUPPRESSIVE AGENTS; INFLAMMATORY BOWEL DISEASES; OPPORTUNISTIC INFECTIONS; PATIENT EDUCATION AS TOPIC; RISK MANAGEMENT; TUMOR NECROSIS FACTOR-ALPHA;

EID: 77950807095     PISSN: 13894501     EISSN: None     Source Type: Journal    
DOI: 10.2174/138945010790310009     Document Type: Review

References (252)

1. Dinarello CA. Anti-cytokine therapeutics and infections. Vaccine 2003; 21: S24-34.
2. Sandborn WJ, Loftus EV. Balancing the risks and benefits of infliximab in the treatment of inflammatory bowel disease. Gut 2004; 53: 780-782 (Pubitemid 38662124)
3. Symmers WS. Opportunistic Infections. The concept of 'opportunistic infections'. Proc R Soc Med 1965; 58: 341-346
4. Korzenik JR. Is Crohn's disease due to defective immunity? Gut 2007; 56: 2-5.
5. Toruner M, Loftus EV Jr, Harmsen WS, Zinsmeister AR, Orenstein R, Sandborn WJ, et al. Risk factors for opportunistic infections in patients with inflammatory bowel disease. Gastroenterology 2008; 134: 929-936 (Pubitemid 351451967)
6. Krok KL, Lichtenstein GR. Nutrition in Crohn's disease. Curr Opin Gastroenterol 2003; 19: 148-153
7. Ainley C, Cason J, Slavin BM, Wolstencroft RA, Thompson RP. The influence of zinc status and malnutrition on immunological function in Crohn's disease. Gastroenterology 1991; 100: 1616-1625
8. Benjamin J, Makharia GK, Kalaivani M, Joshi YK. Nutritional status of patients with Crohn's disease. Indian J Gastroenterol 2008; 27: 195-200.
9. Fidder H, Schnitzler F, Ferrante M, Noman M, Katsanos K, Segaert S, et al. Long term safety of infliximab for the treatment of inflammatory bowel disease: a single-centre cohort study. Gut 2009; 58(4): 501-508
10. Lichtenstein GR, Feagan BG, Cohen RD, Salzberg BA, Diamond RH, Chen DM, et al. Serious infections and mortality in association with therapies for Crohn's disease: TREAT registry. Clin Gastroenterol Hepatol 2006; 4: 621-630
11. Burmester GR, Mease PJ, Dijkmans BA, Gordon K, Lovell D, Panaccione R, et al. Adalimumab safety and mortality rates from global clinical trials of six immune-mediated inflammatory diseases. Ann Rheum Dis 2009; [Epub ahead of print].
12. Sandborn WJ, Rutgeerts P, Enns R, Hanauer SB, Colombel JF, Panaccione R, et al. Adalimumab induction therapy for Crohn's disease previously treated with infliximab. A randomized trial. Ann Intern Med 2007; 146: 829-838 (Pubitemid 351650483)
13. Colombel JF, Sandborn WJ, Rutgeerts P, Enns R, Hanauer SB, Panaccione R, et al. Adalimumab for maintenance of clinical response and remission in patients with Crohn's disease: the CHARM trial. Gastroenterology 2007; 132: 52-65. (Pubitemid 46108762)
14. Colombel JF, Loftus EV Jr, Tremaine WJ, Egan LJ, Harmsen WS, Schleck CD, et al. The safety profile of infliximab in patients with Crohn's disease: the Mayo clinic experience in 500 patients. Gastroenterology 2004; 126: 19-31.
15. Schreiber S, Khaliq-Kareemi M, Lawrance IC, Thomsen OØ, Hanauer SB, McColm J, et al. Maintenance therapy with certolizumab pegol for Crohn's disease. N Engl J Med 2007; 357: 239-250 (Pubitemid 47080388)
16. Winther KV, Jess T, Langholz E, Munkholm P, Binder V. Survival and cause-specific mortality in ulcerative colitis: follow-up of a population-based cohort in Copenhagen County. Gastroenterology 2003; 125: 1576-1582 (Pubitemid 37500420)
17. Caspersen S, Elkjaer M, Riis L, Pedersen N, Mortensen C, Jess T, et al. Infliximab for inflammatory bowel disease in Denmark 1999-2005: clinical outcome and follow-up evaluation of malignancy and mortality. Clin Gastroenterol Hepatol 2008; 6: 1212-1217
18. Rahier JF, Ben-Horin S, Chowers Y, Conlon C, De Munter P, D'Haens G, et al. European evidence-based Consensus on the prevention, diagnosis and management of opportunistic infections in inflammatory bowel disease. J Crohn's Colitis 2009; 3: 47-91.
19. Viget N, Vernier-Massouille G, Salmon-Ceron D, Yazdanpanah Y, Colombel JF. Opportunistic infections in patients with inflammatory bowel disease: prevention and diagnosis. Gut 2008; 57: 549-558 (Pubitemid 351442541)
20. Loly C, Belaiche J, Louis E. Predictors of severe Crohn's disease. Scand J Gastroenterol 2008; 43: 948-954
21. Dye C, Scheele S, Dolin P, Pathania V, Raviglione MC. Consensus statement. Global burden of tuberculosis: estimated incidence, prevalence, and mortality by country. WHO Global Surveillance and Monitoring Project. JAMA 1999; 282: 677-686
22. Aberra FN, Stettler N, Brensinger C, Lichtenstein GR, Lewis JD. Risk for active tuberculosis in inflammatory bowel disease patients. Clin Gastroenterol Hepatol 2007; 5(9): 1070-1075
23. Keane J, Gershon S, Wise RP, Mirabile-Levens E, Kasznica J, Schwieterman WD, et al. Tuberculosis associated with infliximab, a tumor necrosis factor alpha-neutralizing agent. N Engl J Med 2001; 345(15): 1098-1104
24. Ormerod LP, Milburn HJ, Gillespie S. British Thoracic Society Standards of Care Committee. BTS recommendations for assessing risk and for managing Mycobacterium Tuberculosis infection and disease in patients due to start anti-TNF-alpha treatment. Thorax 2005; 60: 800-805
25. Tubach F, Salmon D, Ravaud P, Allanore Y, Goupille P, Bréban M, et al. Risk of tuberculosis is higher with anti-tumor necrosis factor monoclonal antibody therapy than with soluble tumor necrosis factor receptor therapy: The three-year prospective French research axed on tolerance of biotherapies registry. Arthritis Rheum 2009; 60: 1884-1894
26. Obrador A, López San Román A, Muñoz P, Fortún J, Gassull MA. Consensus guidelines on tuberculosis and treatment of inflammatory bowel disease with infliximab. Spanish Working Group on Crohn's disease and Ulcerative Colitis. Gastroenterol Hepatol 2003; 26: 29-33. (Pubitemid 36168874)
27. Mow WS, Abreu-Martin MT, Papadakis KA, Pitchon HE, Targan SR, Vasiliauskas EA. High incidence of anergy in inflammatory bowel disease patients limits the usefulness of PPD screening before infliximab therapy. Clin Gastroenterol Hepatol 2004; 2: 309-313
28. Bocchino M, Matarese A, Bellofiore B, Giacomelli P, Santoro G, Balato N, et al Performance of two commercial blood IFN-gamma release assays for the detection of Mycobacterium tuberculosis infection in patient candidates for anti-TNF-alpha treatment. Eur J Clin Microbiol Infect Dis 2008; 27(10): 907-913
29. Dinser R, Fousse M, Sester U, Albrecht K, Singh M, Köhler H, et al. Evaluation of latent tuberculosis infection in patients with inflammatory arthropathies before treatment with TNF-alpha blocking drugs using a novel flow-cytometric interferon-gamma release assay. Rheumatology (Oxford) 2008; 47(2): 212-218 (Pubitemid 351168235)
30. Piana F, Codecasa LR, Cavallerio P, Ferrarese M, Migliori GB, Barbarano L, et al. Use of a T-cell-based test for detection of tuberculosis infection among immunocompromised patients. Eur Respir J 2006; 28: 31-34 (Pubitemid 44914257)
31. Menzies D, Pai M, Comstock G. Meta-analysis: new tests for the diagnosis of latent tuberculosis infection: areas of uncertainty and recommendations for research. Ann Intern Med 2007; 146: 340-354 (Pubitemid 351650594)
32. Perez JL, Kupper H, Spencer-Green GT. Impact of screening for latent TB before initiating anti-TNF therapy in North America and Europe. Ann Rheum Dis 2005; 64(Suppl 3): 265.
33. Carmona L, Gómez-Reino JJ, Rodríguez-Valverde V, Montero D, Pascual-Gómez E, Mola EM, et al. Effectiveness of recommendations to prevent reactivation of latent tuberculosis infection in patients treated with tumor necrosis factor antagonists. Arthritis Rheum 2005; 52: 1766-1772 (Pubitemid 40852885)
34. Dye C, Watt CJ, Bleed DM, Hosseini SM, Raviglione MC. Evolution of tuberculosis control and prospects for reducing tuberculosis incidence, prevalence, and deaths globally. JAMA 2005; 293: 2767-2775 (Pubitemid 40965089)
35. Rampton DS. Preventing TB in patients with Crohn's disease needing infliximab or other anti-TNF therapy. Gut 2005; 54: 1360-1362
36. Takeuchi T, Tatsuki Y, Nogami Y, Ishiguro N, Tanaka Y, Yamanaka H, et al. Post marketing surveillance of the safety profile of infliximab in 5000 Japanese patients with rheumatoid arthritis. Ann Rheum Dis 2008; 67: 189-194
37. Schnitzler F, Fidder H, Ferrante M, Noman M, Arijs I, Van Assche G, et al. Long-term outcome of treatment with infliximab in 614 patients with Crohn's disease: results from a single-centre cohort. Gut 2009; 58: 492-500.
38. Gómez-Reino JJ, Carmona L, Angel Descalzo M. Risk of tuberculosis in patients treated with tumor necrosis factor antagonists due to incomplete prevention of reactivation of latent infection. Arthritis Rheum 2007; 57: 756-761 (Pubitemid 46932080)
39. Bourikas LA, Kourbeti IS, Koutsopoulos AV, Koutroubakis IE. Disseminated tuberculosis in a Crohn's disease patient on anti-TNFa therapy despite chemoprophylaxis. Gut 2008; 57: 425.
40. Sichletidis L, Settas L, Spyratos D, Chloros D, Patakas D. Tuberculosis in patients receiving anti-TNF agents despite chemoprophylaxis. Int J Tuberc Lung Dis 2006; 10: 1127-1132 (Pubitemid 44519351)
41. Arundal C, Lewis JH. Drug-induced liver disease in 2006. Curr Opin Gastroenterol 2007; 23; 244-254
42. Nolan CM, Goldberg SV, Bushin SE. Hepatotocicity associated with isoniazid preventative therapy: a seven year survey from a public health tuberculosis clinic. JAMA 1999; 281: 1014-1018
43. Lee WM. Drug-induced hepatotoxicity. N Engl J Med 1995; 281: 1014-1018
44. Hernandez-Cruz B, Ponce-de-Leon-Rosales S, Sifuentes-Osornio J. Tuberculosis prophylaxis in patients with steroid treatment and systemic rheumatoid diseases. A case-control study. Clin Exp Rheumatol 1999; 17: 81-87 (Pubitemid 29099892)
45. Almadi MA, Ghosh S, Aljebreen AM. Differentiating intestinal tuberculosis from Crohn's disease: a diagnostic challenge. Am J Gastroenterol 2009; 104: 1003-1012
46. Schneeweiss S, Korzenik J, Solomon DH, Canning C, Lee J, Bressler B. Infliximab and other immunomodulating drugs in patients with inflammatory bowel disease and the risk of serious bacterial infections. Aliment Pharmacol Ther 2009; 30: 253-264
47. Melmed GY, Ippoliti AF, Papadakis KA, Tran TT, Birt JL, Lee SK, et al. Patients with inflammatory bowel disease are at risk for vaccine-preventable illnesses. Am J Gastroenterol 2006; 101: 1834-1840 (Pubitemid 44166594)
48. Farah R, Lisitsin S, Shay M. Bacterial meningitis associated with infliximab. Pharm World Sci 2006; 28: 123-125
49. Chan AT, Cleeve V, Daymond TJ. Necrotising fasciitis in a patient receiving infliximab for rheumatoid arthritis. Postgrad Med J 2002; 78: 47-48 (Pubitemid 34074917)
50. Kida Y, Harada Y, Tachikawa R, Hata A, Kaji R, Takeshima Y, et al. A case of cavitating pneumococcal pneumonia developed during the treatment with etanercept for rheumatoid arthritis. Nihon Kokyuki Gakkai Zasshi 2009; 47: 320-325
51. Zimmer C, Beiderlinden M, Peters J. Lethal acute respiratory distress syndrome during anti-TNF-alpha therapy for rheumatoid arthritis. Clin Rheumatol 2006; 25: 430-432
52. Ritz MA, Jost R. Severe pneumococcal pneumonia following treatment with infliximab for Crohn's disease. Inflamm Bowel Dis 2001; 7: 327.
53. Targonski PV, Poland GA. Pneumococcal vaccination in adults: recommendations, trends and prospects. Cleve Clin J Med 2007; 74: 401-424
54. Kapetanovic MC, Saxne T, Sjöholm A, Truedsson L, Jönsson G, Geborek P. Influence of methotrexate, TNF blockers and prednisolone on antibody responses to pneumococcal polysaccharide vaccine in patients with rheumatoid arthritis. Rheumatology (Oxford) 2006; 45: 106-111
55. Visvanathan S, Keenan GF, Baker DG, Levinson AI, Wagner CL. Response to pneumococcal vaccine in patients with early rheumatoid arthritis receiving infliximab plus methotrexate or methotrexate alone. J Rheumatol 2007; 34: 952-957
56. Beigel F, Jürgens M, Filik L, Bader L, Lück C, Göke B, et al. Severe Legionella pneumophila pneumonia following infliximab therapy in a patient with Crohn's disease. Inflamm Bowel Dis 2009; 15: 1240-1244
57. Dederichs F, Pinciu F, Gerhard H, Eveld K, Stallmach A. Listeria meningitis in a patient with Crohn's disease - a seldom, but clinically relevant adverse event of therapy with infliximab. Z Gastroenterol 2006; 44 : 657-660
58. Armitage K, Woodhead M. New guidelines for the management of adult community-acquired pneumonia. Curr Opin Infect Dis 2007; 20: 170-176
59. Bassetti M, Nicco E, Delfino E, Viscoli C. Disseminated Salmonella paratyphi infection in a rheumatoid arthritis patient treated with infliximab. Clin Microbiol Infect 2009; In press.
60. Rijkeboer A, Voskuyl A, Van Agtmael M. Fatal Salmonella enteritidis septicaemia in a rheumatoid arthritis patient treated with a TNF-alpha antagonist. Scand J Infect Dis 2007; 39: 80-83
61. Katsarolis I, Tsiodras S, Panagopoulos P, Giannitsioti E, Skarantavos G, Ioannidis T, et al. Septic arthritis due to Salmonella enteritidis associated with infliximab use. Scand J Infect Dis 2005; 37(4): 304-305
62. Fu A, Bertouch JV, McNeil HP. Disseminated Salmonella typhimurium infection secondary to infliximab treatment. Arthritis Rheum 2004; 50 (9): 3049.
63. Rim JY, Tenorio AR. Salmonella septic arthritis in a patient with Crohn's disease on infliximab. Inflamm Bowel Dis 2009; [Epub].
64. Sandford J. The Sandford guide to antimicrobial therapy; 2006-2007.
65. Bowie VL, Snella KA, Gopalachar AS, Bharadwaj P. Listeria meningitis associated with infliximab. Ann Pharmacother 2004;38: 58-61.
66. Izbéki F, Nagy F, Szepes Z, Kiss I, Lonovics J, Molnár T. Severe Listeria meningoencephalitis in an infliximab-treated patient with Crohn's disease. Inflammatory bowel diseases 2008; 14: 4298-4331
67. Kesteman T, Yombi JC, Gigi J, Durez P. Listeria infections associated with infliximab: case reports. Clin Rheumatol 2007; 26: 2173-2175
68. Slifman NR, Gershon SK, Lee JH, Edwards ET, Braun MM. Listeria monocytogenes infection as a complication of treatment with tumor necrosis factor alpha-neutralizing agents. Arthritis Rheum 2003; 48: 319-324
69. Tweezer-Zaks N, Shiloach E, Spivak A, Rapoport M, Novis B, Langevitz P. Listeria monocytogenes sepsis in patients treated with anti-tumor necrosis factor-alpha. IMAJ 2003; 5: 829-830
70. Wing EJ, Gregory SH. Listeria monocytogenes: clinical and experimental update. J Infect Dis 2002; 185(Suppl 1): S18-24.
71. Dinarello CA. Anti-cytokine therapeutics and infections. Vaccine 2003; 21(Suppl 2: S24-34.
72. Dederichs F, Pinciu F, Gerhard H, Eveld K, Stallmach A. Listeria meningitis in a patient with Crohn's disease - a seldom, but clinically relevant adverse event of therapy with infliximab. Z Gastroenterol 2006; 44: 657-660
73. Rodemann JF, Dubberke ER, Reske KA, Seo da H, Stone CD. Incidence of Clostridium difficile infection in inflammatory bowel disease. Clin Gastroenterol Hepatol 2007; 5: 339-344
74. Ananthakrishnan AN, McGinley EL, Binion DG. Excess hospitalisation burden associated with Clostridium difficile in patients with inflammatory bowel disease. Gut 2008; 57: 205-210
75. Lamontagne F, Labbé AC, Haeck O, Lesur O, Lalancette M, Patino C, et al. Impact of emergency colectomy on survival of patients with fulminant Clostridium difficile colitis during an epidemic caused by a hypervirulent strain. Ann Surg 2007; 245: 267-272
76. Elliot B, Chang BJ, Golledge CL, Riley TV. Clostridium difficile-associated diarrhoea. Intern Med J 2007; 37: 561-568
77. McFarland LV, Elmer GW, Surawicz CM. Breaking the cycle: treatment strategies for 163 cases of recurrent Clostridium difficile disease. Am J Gastroenterol 2002; 97: 1769-1775
78. Goodman MJ, Truelove SC. Intensive intravenous regimen for membranous colitis. BMJ 1976; 2: 354.
79. McFarland LV. Meta-analysis of probiotics for the prevention of antibiotic associated diarrhoea and the treatment of clostridium difficile disease. Am J Gastroenterol 2006; 101: 812-822
80. Cherifi S, Robberecht J, Miendje Y. Saccharomyces cerevisiae fungemia in an elderly patient with Clostridium difficile colitis. Acta Clin Belg 2004; 59: 223-224
81. Riquelme AJ, Calvo MA, Guzmán AM, Depix MS, García P, Pérez C, et al. Saccharomyces cerevisiae fungemia after Saccharomyces boulardii treatment in immunocompromised patients. J Clin Gastroenterol 2003; 36(1): 41-43
82. Al-Tawfiq JA, Al-Khatti AA. Disseminated systemic Nocardia farcinica infection complicating alefacept and infliximab therapy in a patient with severe psoriasis. Int J Infect Dis 2009. [Epub]
83. Fabre S, Gibert C, Lechiche C, Jorgensen C, Sany J. Primary cutaneous Nocardia otitidiscaviarum infection in a patient with rheumatoid arthritis treated with infliximab. J Rheumatol 2005; 32: 2432-2433 (Pubitemid 41780660)
84. Stratakos G, Kalomenidis I, Papas V, Malagari K, Kollintza A, Roussos C, et al. Cough and fever in a female with Crohn's disease receiving infliximab. Eur Respir J 2005; 26: 354-357
85. Singh SM, Rau NV, Cohen LB, Harris H. Cutaneous nocardiosis complicating management of Crohn's disease with infliximab and prednisone. JAMC 2004; 171: 1063-1064
86. Menon KV, Stadheim L, Kamath PS, Wiesner RH, Gores GJ, Peine CJ, et al. A pilot study of the safety and tolerability of etanercept in patients with alcoholic hepatitis. Am J Gastroenterol 2004; 99: 255-260
87. Yildz O, Doganay M. Actinomycoses and Norcardia pulmonary infections. Curr Opin Pulm Med 2006; 12: 228-234
88. Shale MJ, Seow C, S Coffin C, G Kaplan G, Panaccione R, Ghosh S. Review article: Chronic viral infection in the anti-tumour necrosis factor therapy era in inflammatory bowel disease. Aliment Pharmacol Ther 2009; [Epub ahead of print].
89. Wong GH, Goeddel DV. Tumour necrosis factors alpha and beta inhibit virus replication and synergize with interferons. Nature 1986; 323: 819-822
90. Schlaak JF, Tully G, Löhr HF, Gerken G, Meyer zum Büschenfelde. HBV-specific immune defect in chronic hepatitis B is correlated with a dysregulation of pro- and anti-inflammatory cytokines. Clin Exp Immunol 1999; 115: 508-514
91. Nathan DM, Angus PW, Gibson PR. Hepatitis B and C virus infections and anti-tumor necrosis factor-alpha therapy: guidelines for clinical approach. J Gastroenterol Hepatol 2006; 21: 366-371
92. Oniankitan O, Duvoux C, Challine D, Mallat A, Chevalier X, Pawlotsky JM, et al. Infliximab therapy for rheumatic diseases in patients with chronic hepatitis B or C. J Rheumatol 2004; 31: 107-109
93. del Valle García-Sánchez M, Gómez-Camacho F, Poyato-González A, Iglesias-Flores EM, de Dios-Vega JF, Sancho-Zapatero R. Infliximab therapy in a patient with Crohn's disease and chronic hepatitis B virus infection. Inflamm Bowel Dis 2004; 10: 701-702
94. Peterson JR, Hsu FC, Simkin PA, Wener MH. Effect of tumour necrosis factor alpha antagonists on serum transaminases and viraemia in patients with rheumatoid arthritis and chronic hepatitis C infection. Ann Rheum Dis 2003; 62: 1078-1082
95. Esteve M, Saro C, González-Huix F, Suarez F, Forné M, Viver JM. Chronic hepatitis B reactivation following infliximab therapy in Crohn's disease patients: need for primary prophylaxis. Gut 2004; 53: 1363-1365
96. Millonig G, Kern M, Ludwiczek O, Nachbaur K, Vogel W. Subfulminant hepatitis B after infliximab in Crohn's disease: need for HBV-screening? World J Gastroenterol 2006; 12: 974-976
97. Lavagna A, Bergallo M, Daperno M, Sostegni R, Costa C, Leto R, et al. Infliximab and the risk of latent viruses reactivation in active Crohn's disease. Inflamm Bowel Dis 2007; 13: 896-902.
98. Ojiro K, Naganuma M, Ebinuma H, Kunimoto H, Tada S, Ogata H, et al. Reactivation of hepatitis B in a patient with Crohn's disease treated using infliximab. J Gastroenterol 2008; 43: 397-401.
99. Madonia S, Orlando A, Scimeca D, Olivo M, Rossi F, Cottone M. Occult hepatitis B and infliximab-induced HBV reactivation. Inflamm Bowel Dis 2007; 13: 508-509
100. Scherzer TM, Staufer K, Novacek G, Steindl-Munda P, Schumacher S, Hofer H, et al. Efficacy and safety of antiviral therapy in patients with Crohn's disease and chronic hepatitis C. Aliment Pharmacol Ther 2008; 28: 742-748
101. Tilg H, Vogelsang H, Ludwiczek O, Lochs H, Kaser A, Colombel JF, et al. A randomised placebo controlled trial of pegylated interferon alpha in active ulcerative colitis. Gut 2003; 52: 1728-1733
102. Lok AS, McMahon BJ. AASLD Practice Guidelines. Chronic Hepatitis B: Update 2009. Hepatology 2009; 50: 1-36.
103. Campbell S, Gosh S. Infliximab therapy for Crohn's disease in the presence of chronic hepatitis C infection. Eur J Gastroenterol Hepatol 2001; 13: 191-192
104. Magliocco MA, Gottlieb AB. Etanercept therapy for patients with psoriatic arthritis and concurrent hepatitis C infection: report of 3 cases. J Am Acad Dermatol 2004; 51: 580-584
105. Parke FA, Reveille JD. Anti-tumour necrosis factor agents for rheumatoid arthritis in the setting of chronic hepatitis C infection. Arth Rheum 2004; 51: 800-804
106. Valcoup C, Krzysiek R, Greangeot-Keros L, Wendling D, Goupille P, Brault R, et al. Effect of tumour necrosis factor antagonist treatment of hepatitis C-related immunological abnormalities. Eur Cytokine Netw 2006; 17: 290-293
107. Peterson JR, Hsu FC, Simkin PA, Wener MH. Effect of tumour necrosis factor alpha antagonists on serum transaminases and viraemia in patients with rheumatoid arthritis and chronic hepatitis C infection. Ann Rheum Dis 2003; 62: 1078-1082
108. Ferri C, Ferraccioli G, Ferrari D, Galeazzi M, Lapadula G, Montecucco C, et al. Safety of anti-tumor necrosis factor-alpha therapy in patients with rheumatoid arthritis and chronic hepatitis C virus infection. J Rheumatol 2008; 35: 1944-1949
109. Zein NN. Etanercept as an adjuvant to interferon and ribavirin in treatment naïve patients with chronic hepatitis C virus infection: a phase 2 randomised double-blind, placebo controlled study. J Hepatol 2005; 42: 315-322
110. Duh EJ, Maury WJ, Folks TM, Fauci AS, Rabson AB. Tumor necrosis factor alpha activates human immune deficiency virus type 1 through induction of nuclear factor binding to the NF-kappa B sites in the long terminal repeat. Proc Natl Acad Sci USA 1989; 89: 5974-5978
111. Calabrese LH, Zein N, Vassilopouslos D. Safety of anti tumour necrosis factor (anti-TNF) therapy in patients with chronic viral infections: hepatitis C, hepatitis B, and HIV infection. Ann Rheum Dis 2004; 63(Suppl 2): ii18-24.
112. Cepeda EJ, Williams FM, Ishimori ML, Weisman MH, Reveille JD. The use of anti-tumour necrosis factor therapy in HIV-positive individuals with rheumatic disease. Ann Rheum Dis 2008; 67: 710-712
113. Walker RE, Spooner KM, Kelly G, McCloskey RV, Woody JN, Falloon J, et al. Inhibition of immunoreactive tumor necrosis factor-alpha by a chimeric antibody in patients infected with human immunodeficiency virus type 1. J Infect Dis 1996; 174: 63-68
114. Sha BE, Valdez H, Gelman RS, Landay AL, Agosti J, Mitsuyasu R, et al. Effect of Etanecept (Enbrel) on interleukine-6, tumor necrosis factor-alpha and marker of immune activation in HIV-infected subjects receiving interleukin 2. AIDS Res Hum Retroviruses 2002; 18: 661-665
115. Wallis RS, Kyambadde P, Johnson JL, Horter L, Kittle R, Pohle M, et al. A study of the safety, immunology, virology and microbiology of adjunctive etanercept in HIV-1-associated tuberculosis. AIDS 2004; 18: 257-264
116. Beltrán B, Nos P, Bastida G, Iborra M, Hoyos M, Ponce J. Safe and effective application of anti-TNF-alpha in a patient infected with HIV and concomitant Crohn's disease. Gut 2006; 55: 1670-1671
117. Hashida S, Hashinaka K, Nishikata I, Saito A, Takamizawa A, Shinagawa H, et al. Earlier diagnosis of HIV-1 infection by simultaneous detection of p24 antigen and antibody IgGs to p17 and reverse transcriptase in serum with enzyme immunoassay. J Clin Lab Anal 1996; 10: 213-219 (Pubitemid 26243005)
118. Chen LF, Hoy J, Lewin SR. Ten years of highly active antiretroviral therapy for HIV infection. Med J Aust 2007; 186: 146-151
119. D'Ovidio V, Vernia P, Gentile G, Capobianchi A, Marcheggiano A, Viscido A, et al. Cytomegalovirus infection in inflammatory bowel disease patients undergoing anti-TNFalpha therapy. J Clin Virol 2008; 43: 180-183
120. Helbling D, Breitbach TH, Krause M. Disseminated cytomegalovirus infection in Crohn's disease following anti-tumour necrosis factor therapy. Eur J Gastroenterol Hepatol 2002; 14: 1393-1395 (Pubitemid 36054931)
121. Haerter G, Manfras BJ, de Jong-Hesse Y, Wilts H, Mertens T, Kern P, et al. Cytomegalovirus retinitis in a patient treated with antitumor necrosis factor alpha antibody therapy for rheumatoid arthritis. Clin Infect Dis 2004; 39: e88-94.
122. Sari I, Birlik M, Gonen C, Akar S, Gurel D, Onen F, Akkoc N. Cytomegalovirus colitis in a patient with Behcet's disease receiving tumor necrosis factor alpha inhibitory treatment. World J Gastroenterol 2008; 14: 2912-2914
123. Taylor GH. Cytomegalovirus. Am Fam Physician 2003; 67: 519-524
124. Gerna G, Zavattoni M, Percivalle E, Zella D, Torsellini M, Revello MG. Diagnosis of human cytomegalovirus infections in the immunocompromised host. Clin Diagn Virol 1996; 5: 181-186 (Pubitemid 26261031)
125. Kandiel A, Lashner B. Cytomegalovirus colitis complicating inflammatory bowel disease. Am J Gastroenterol 2006; 101: 2857-2865
126. Kishore J, Ghoshal U, Ghoshal UC, Krishnani N, Kumar S, Singh M, et al. Infection with cytomegalovirus in patients with inflammatory bowel disease: prevalence, clinical significance and outcome. J Med Microbiol 2004; 53: 1155-1160 (Pubitemid 40052501)
127. Ayre K, Warren BF, Jeffrey K, Travis SPL. The role of CMV in steroid-resistant ulcerative colitis: a systematic review. J Crohn's Colitis 2009; 3: 141-148
128. Fatahzadeh M, Schwartz RA. Human herpes simplex virus infections: epidemiology, pathogenesis, symptomatology, diagnosis and management. J Am Acad Dermatol 2007; 57: 737-763
129. Alimohamadi SM, Malekzadeh R, Mirmadjless SH, Mohamadnejad M, Zamani F. Herpes simplex viral encephalitis during immunosuppressive treatment of ulcerative colitis. Med Gen Med 2004; 6: 7.
130. Shlien RD, Meyers S, Lee JA, Dische R, Janowitz HD. Fulminant herpes simplex hepatitis in a patient with ulcerative colitis. Gut 1988; 29: 257-261 (Pubitemid 18078898)
131. Schunter M. Herpes simplex colitis complicating ulcerative colitis: a case report and brief review on superinfections. JCC 2007; 1: 41-46 (Pubitemid 350265731)
132. El-Serag HB, Zwas FR, Cirillo NW, Eisen RN. Fulminant herpes colitis in a patient with Crohn's disease. J Clin Gastroenterol 1996; 22: 220-223 (Pubitemid 26118629)
133. Bradford RD, Pettit AC, Wright PW, Mulligan MJ, Moreland LW, McLain DA, et al. Herpes simplex encephalitis during treatment with tumor necrosis factor-alpha inhibitors. Clin Infect Dis 2009; 49: 924-927
134. van der Klooster JM, Bosman RJ, Oudemans-van Straaten HM, van der Spoel JI, Wester JP, Zandstra DF. Disseminated tuberculosis, pulmonary aspergillosis and cutaneous herpes simplex infection in a patient with infliximab and methotrexate. Intensive Care Med 2003; 29: 2327-2329
135. Justice EA, Khan SY, Logan S, Jobanputra P. Disseminated cutaneous Herpes Simplex Virus-1 in a woman with rheumatoid arthritis receiving Infliximab: A case report. J Med Case Reports 2008; 2: 282.
136. Wiland P, Głowska A, Chlebicki A, Szechiński J. Analysis of efficacy and safety of multiple intravenous infusion of anti-tumor necrosis factor-alpha monoclonal antibody (Remicade) combined with methotrexate compared with sodium aurothiomalate and intramuscular depot methylprednisolone in rheumatoid arthritis. Pol Arch Med Wewn 2002; 108: 1055-1063 (Pubitemid 36007803)
137. Martinez V, Caumes E, Chosidow O. Treatment to prevent recurrent genital herpes. Curr Opin Infect Dis 2008; 21: 42-48
138. Sampathkumar P, Drage LA, Martin DP. Herpes zoster (shingles) and postherpetic neuralgia. Mayo Clin Proc 2009; 84(3): 274-280
139. Thomas SL, Hall AJ. What does epidemiology tell us about risk factors for herpes zoster? Lancet Infect Dis 2004; 4(1): 26-33.
140. Ricart E, Panaccione R, Loftus EV, Tremaine WJ, Sandborn WJ. Infliximab for Crohn's disease in clinical practice at the Mayo Clinic: the first 100 patients. Am J Gastroenterol 2001; 96: 722-729 (Pubitemid 32240722)
141. Mauillon J, Tranvouez JL. Severe varicella infection during treatment with infliximab for Crohn's disease. Gastroenterol Clin Biol 2006; 30(12): 1410-1413 (Pubitemid 46064238)
142. Leung VS, Nguyen MT, Bush TM. Disseminated primary varicella after initiation of infliximab for Crohn's disease. Am J Gastroenterol 2004; 99: 2503-2504 (Pubitemid 40039388)
143. Vonkeman H, ten Napel C, Rasker H, van de Laar M. Disseminated primary varicella infection during infliximab treatment. J Rheumatol 2004; 31: 2517-2518
144. Choi HJ, Kim MY, Kim HO, Park YM. An atypical varicella exanthem associated with the use of infliximab. Int J Dermatol 2006; 45: 999-1000.
145. Kinder A, Stephens S, Mortimer N, Sheldon P. Severe herpes zoster after infliximab infusion. Postgrad Med J 2004; 80: 26. (Pubitemid 38221879)
146. [146a] Strangfeld A, Listing J, Herzer P, Liebhaber A, Rockwitz K, Richter C, et al. Risk of herpes zoster in patients with rheumatoid arthritis treated with anti-TNF-α agents. JAMA 2009; 301: 737-744
147. [146b] Gnann JW Jr. Vaccination to prevent herpes zoster in older adults. J Pain 2008; 9(Suppl 1): S31-6.
148. Yawn BP, Saddier P, Wollan PC, St Sauver JL, Kurland MJ, Sy LS. A population-based study of the incidence and complication rates of herpes zoster before zoster vaccine introduction. Mayo Clin Proc 2007; 82: 1341-1349 (Pubitemid 350060129)
149. Schmader K, Gnann JW Jr, Watson CP. The epidemiological, clinical, and pathological rationale for the herpes zoster vaccine. J Infect Dis 2008; 197(Suppl 2): S207-15. (Pubitemid 351590173)
150. Harpaz R, Ortega-Sanchez IR, Seward JF, Advisory Committee on Immunization Practices (ACIP), Centers for Disease Control and Prevention (CDC). Prevention of herpes zoster: recommendations of the Advisory Committee on Immunization Practices (ACIP) [published correction appears in MMWR Recomm Rep. 2008; 57(28): 779. MMWR Recomm Rep 2008; 57(RR-5): 1-30.
151. Sands BE, Cuffari C, Katz J, Kugathasan S, Onken J, Vitek C, et al. Guidelines for immunizations in patients with inflammatory bowel disease. Inflam Bowel Dis 2004; 10: 677-692 (Pubitemid 39276481)
152. Whitley RJ, Weiss H, Gnann JW Jr, Tyring S, Mertz GJ, Pappas PG, et al. The National Institute of Allergy and Infectious Diseases Collaborative Antiviral Study Group. Acyclovir with and without prednisone for the treatment of herpes zoster: a randomized, placebo-controlled trial. Ann Intern Med 1996; 125: 376-383
153. Wood MJ, Johnson RW, McKendrick MW, Taylor J, Mandal BK, Crooks J. A randomized trial of acyclovir for 7 days or 21 days with and without prednisolone for treatment of acute herpes zoster. N Engl J Med 1994; 330: 896-900. (Pubitemid 24094969)
154. Ahmed AM, Brantley JS, Madkan V, Mendoza N, Tyring SK. Managing herpes zoster in immunocompromised patients. Herpes 2007; 14: 32-36
155. Posthuma EF, Westendorp RG, van der Sluys Veer A, Kluin-Nelemans JC, Kluin PM, Lamers CB. Fatal infectious mononucleosis: a severe complication in the treatment of Crohn's disease with azathioprine. Gut 1995; 36: 311-313
156. Dayharsh GA, Loftus EV Jr, Sandborn WJ, Tremaine WJ, Zinsmeister AR, Witzig TE, et al. Epstein-Barr virus positive lymphoma in patients with inflammatory bowel disease treated with azathioprine or 6-mercaptopurine. Gastroenterology 2002; 122: 72-77
157. Bai M, Katsanos KH, Economou M, Kamina S, Balli C, Briasoulis E, et al.
158. Brown SL, Greene MH, Gershon SK, Edwards ET, Braun MM. Tumor necrosis factor antagonist therapy and lymphoma development: twenty six cases reported to the Food and Drug Administration. Arthritis Rheum 2002; 46: 3151-3158
159. Juffermans NP, Jager A, Kersten MJ, van Oers MH, Hommes DW. Epstein-Barr virus related lymphoma in patients with inflammatory bowel disease. Ned Tijdschr Geneeskd 2005; 149: 1859-1863
160. Lavagna A, Bergallo M, Daperno M, Sostegni R, Costa C, Leto R, et al. Infliximab and the risk of latent viruses reactivation in active Crohn's disease. Inflamm Bowel Dis 2007; 13: 896-902.
161. Reijasse D, Le Pendeven C, Cosnes J, Dehee A, Gendre JP, Nicolas JC, et al. Epstein-Barr virus viral load in Crohn's disease: effect of immunosuppressive therapy. Inflamm Bowel Dis 2004; 10: 85-90.
162. McKeown E, Pope JE, Leaf S. Epstein-Barr Virus (EBV) Prevalence and the risk of reactivation in patients with inflammatory arthritis using Anti-TNF agents and in those who are Biologic Naive. Open Rheumatol J 2009; 3: 30-34
163. Funch DP, Walker AM, Schneider G, Ziyadeh NJ, Pescovitz MD. Ganciclovir and acyclovir reduce the risk of post transplant lymphoproliferative disorder in renal transplant recipients. Am J Transplant 2005; 5: 2894-2900
164. Salloum E, Cooper DL, Howe G, Lacy J, Tallini G, Crouch J, et al. Spontaneous regression of lymphoproliferative disorders in patients treated with methotrexate for rheumatoid arthritis and other rheumatic diseases. J Clin Oncol 1996; 14: 1943-1949
165. Omer SB, Salmon DA, Orenstein WA, DeHart P, Halsey N. Vaccine refusal, mandatory immunization and the risks of vaccine-preventable diseases. N Engl J Med 2009; 360: 1981-1988
166. Lu Y, Jacobson DL, Ashworth LA, Grand RJ, Meyer AL, McNeal MM, et al. Immune response to influenza vaccine in children with inflammatory bowel disease. Am J Gastroenterol 2009; 104: 444-453
167. Fields SW, Baiocco PJ, Korelitz BI. Influenza vaccinations: should they really be encouraged for IBD patients being treated with immunosuppressives? Inflamm Bowel Dis 2009; 15: 649-51; author reply 651-652
168. Lu Y, Jacobson D, Bousvaros A. Immunizations in patients with inflammatory bowel disease. Inflamm Bowel Dis 2009; 15: 1417-1423
169. Kwon OS, Park YS, Choi JH, Kim SH, Song MH, Lee HH, et al. [A case of ulcerative colitis relapsed by influenza vaccination] Korean J Gastroenterol 2007; 49: 327-330
170. Mamula P, Markowitz JE, Piccoli DA, Klimov A, Cohen L, Baldassano RN. Immune response to influenza vaccine in pediatric patients with inflammatory bowel disease. Clin Gastroenterol Hepatol 2007; 5: 851-856
171. Fomin I, Caspi D, Levy V, Varsano N, Shalev Y, Paran D, et al. Vaccination against influenza in rheumatoid arthritis: the effect of disease modifying drugs, including TNF alpha blockers. Ann Rheum Dis 2006; 65: 191-194
172. Gelinck LB, van der Bijl AE, Beyer WE, Visser LG, Huizinga TW, van Hogezand RA, et al. The effect of anti-tumour necrosis factor alpha treatment on the antibody response to influenza vaccination. Ann Rheum Dis 2008; 67: 713-716
173. Monto AS, Fleming DM, Henry D, de Groot R, Makela M, Klein T, et al. Efficacy and safety of the neuraminidase inhibitor zanamivir in the treatment of influenza type A and B virus infections. J Infect Dis 1999; 180: 254-261
174. Nicholson KG, Aoki FY, Osterhaus AD, Trottier S, Carewicz O, Mercier CH, et al. Efficacy and safety of oseltamir in the treatment of acute influenza: a randomised controlled trial. Neuraminidase Inhibitor Flu Treatment Investigator Group. Lancet 2000; 355: 1845-1850
175. Novel Swine-Origin Influenza A (H1N1) Virus Investigation Team, Dawood FS, Jain S, Finelli L, Shaw MW, Lindstrom S, Garten RJ, et al. Emergence of a novel swine-origin influenza A (H1N1) virus in humans. N Engl J Med 2009; 360: 2605-2615
176. McCullers JA. Insights into the interaction between influenza virus and pneumococcus. Clin Microbiol Rev 2006; 19: 571-582
177. European Centre for Disease Prevention and Control. Public health use of influenza antivirals during influenza pandemics. August 2009. http://ecdc.europa.eu/en/publications/Publications/0907-GUI-Public-Health-use- of-Influenza-Antivirals-during-Influenza-Pandemic.pdf
178. Rahier JF, Yazdanpannah Y, Travis SPL, Colombel JF. Influenza A (H1N1) virus in patients with inflammatory bowel disease. Aliment Pharmacol Ther 2009; [Epub ahead of print].
179. Munoz N. Human papilloma virus and cancer: the epidemiological evidence. J Clin Virol 2000; 19: 1-5.
180. Muñoz N, Bosch FX, de Sanjosé S, Herrero R, Castellsagué X, Shah KV, et al. Epidemiological classification of human papillomavirus types associated with cervical cancer. N Engl J Med 2003; 348(6): 518-527
181. Bhatia J, Bratcher J, Korelitz B, Vakher K, Mannor S, Shevchuk M, et al. Abnormalities of the uterine cervix in women with inflammatory bowel disease. World J Gastroenterol 2006; 12: 6167-6171
182. Kane S, Khatibi B, Reddy D. Higher incidence of abnormal Pap smears in women with inflammatory bowel disease. Am J Gasteroenterol 2008; 103: 631-636
183. Singh H, Demers AA, Nugent Z, Mahmud SM, Kliewer EV, Bernstein CN. Risk of cervical abnormalities in women with inflammatory bowel disease: a population-based nested case-control study. Gastroenterology 2009; 136: 451-458
184. Kane S. Abnormal Pap smears in inflammatory bowel disease. Inflamm Bowel Dis 2008; 14 (8): 1158-1160
185. Petry KU, Köchel H, Bode U, Schedel I, Niesert S, Glaubitz M, et al. Human papillomovirus is associated with the frequent detection of warty and basaloid high-grade neoplasia of the vulva and cervical neoplasia among immunocompromised women. Gynecol Oncol 1996; 60: 30-34
186. Antoniou C, Kosmadaki MG, Stratigos AJ, Katsambas AD. Genital HPV lesions and molluscum contagiosum occurring in patients receiving anti-TNF-alpha therapy. Dermatology 2008; 216: 364-365
187. Cursiefen C, Grunke M, Dechant C, Antoni C. Multiple bilateral eyelid molluscum contagiosum lesions associated with TNF alpha-antibody and methotrexate therapy. Am J Ophthalmol 2002; 134: 270-271
188. Long MD, Porter CQ, Sandler RS, Kappelman MD. Suboptimal rates of cervical testing among women with inflammatory bowel disease. Clin Gastroenterol Hepatol 2009; 7: 549-553
189. Hutfless S, Fireman B, Kane S, Herrinton LJ. Screening differences and risk of cervical cancer in inflammatory bowel disease. Aliment Pharmacol Ther 2008; 28: 598-605.
190. ACOG. Practice Bulletin. Clinical Management Guidelines for Obstetricians-Gynaecologists. Number 61. Human papillomavirus. Obstet Gynecol 2005; 105: 905-918
191. Major EO. Progressive multifocal leukoencephalopathy in patients on immunomodulatory therapies. Annu Rev Med 2009; [Epub ahead of print].
192. Clifford DB. Natalizumab and PML: a risky business? Gut 2008; 57 (10): 1347-1349
193. Carson KR, Focosi D, Major EO, Petrini M, Richey EA, West DP, et al. Monoclonal antibody-associated progressive multifocal leucoencephalopathy in patients treated with rituximab, natalizumab, and efalizumab: a Review from the Research on Adverse Drug Events and Reports (RADAR) Project. Lancet Oncol 2009; 10: 816-824
194. Chen Y, Bord E, Tompkins T, Miller J, Tan CS, Kinkel RP, et al. Asymptomatic reactivation of JC virus in patients treated with natalizumab. N Engl J Med 2009; 361: 1067-1074
195. Adelman B, Sandrock A, Panzara MA. Natalizumab and progressive multifocal leukoencephalopathy. N Engl J Med 2005; 353: 432-433
196. [194a] Lindå H, von Heijne A, Major EO, Ryschkewitsch C, Berg J, Olsson T, et al. Progressive multifocal leukoencephalopathy after natalizumab monotherapy. N Engl J Med 2009; 361: 1081-1087
197. FDA. Warns of safety concern regarding rituxan in new patient population. http://www.hbmsp.sipa.gov.tw:9090/itri/en/images/Risk6-2.htm
198. Wallis RS, Broder MS, Wong JY, Hanson ME, Beenhouwer DO. Granulomatous infectious diseases associated with tumour necrosis factor antagonists. Clin Infect Dis 2004; 38: 1261-1265
199. Tsiodras S, Samonis G, Boumpas DT, Kontoyiannis DP. Fungal infections complicating tumor necrosis factor alpha blockade therapy. Mayo Clin Proc 2008; 83: 181-219
200. Kaur N, Mahl TC. Pneumocystis carinii pneumonia with oral candidaisis after infliximab therapy for Crohn's disease. Dig Dis Sci 2004; 49: 1458-1460
201. Ricart E, Panaccione R, Loftus EV, Tremaine WJ, Sandborn WJ. Infliximab for Crohn's disease in clinical practice: the first 100 patients. Am J Gastroenterol 2001; 96: 722-729
202. Chang A, Neofytos D, Horn D. Candidemia in the 21st century. Future Microbiol 2008; 3: 463-472
203. Warris A, Bjorneklett A, Gaustad P. Invasive pulmonary aspergillosis associated with infliximab therapy. N Engl J Med 2001; 344: 1099-1100
204. Manz M, Beglinger C, Vavricka SR. Fatal invasive pulmonary aspergillosis associated with adalimumab therapy. Gut 2009; 58: 149.
205. Segal BH. Aspergillosis. N Engl J Med 2009; 360: 1870-1884
206. Lai CC, Tan CK, Huang YT, Shao PL, Hsueh PR. Current challenges in the management of invasive fungal infections. J Infect Chemother 2008; 14: 77-85.
207. Lee JH, Slifman NR, Gershon SK, Edwards ET, Schwieterman WD, Siegel JN, et al. Life-threatening histoplasmosis complicating immunotherapy with tumor necrosis factor alpha antagonists infliximab and etanercept. Arthritis Rheum 2002; 46: 2565-2570
208. Jain VV, Evans T, Peterson MW. Reactivation histoplasmosis after treatment with anti-tumor necrosis factor alpha in a patient from a nonendemic area. Respir Med 2006; 100: 1291-1293
209. Nakelchik M, Mangino JE. Reactivation of histoplasmosis after treatment with infliximab. Am J Med 2002; 112: 78.
210. Wood KL, Hage CA, Knox KS, Kleiman MB, Sannuti A, Day RB, et al. Histoplasmosis after treatment with anti-tumor necrosis factor-alpha therapy. Am J Respir Crit Care Med 2003; 167: 1279-1282
211. Rutgeerts P, Van Assche G, Vermeire S. Review article: Infliximab therapy for inflammatory bowel disease seven years on. Aliment Pharmacol Ther 2006; 23: 451-463
212. Kauffman CA. Diagnosis of histoplasmosis in immunosuppressed patients. Curr Opin Infect Dis 2008; 21: 421-425
213. Kauffman CA. Histoplasmosis. Clin Chest Med 2009; 30: 217-225
214. Arend SM, Kuijper EJ, Allaart CF. Cavitating pneumonia after treatment with infliximab and prednisolone. Eur J Clin Microbiol Infect Dis 2004; 23: 638-641
215. Hage CA, Wood KL, Winer-Muram HT, Wilson SJ, Sarosi G, Knox KS. Pulmonary cryptococcosis after initiation of anti-tumor necrosis factor-alpha therapy. Chest 2003; 124: 2395-2397
216. Muñoz P, Giannella M, Valerio M, Soria T, Díaz F, Longo JL, et al. Cryptococcal meningitis in a patient treated with infliximab. Diagn Microbiol Infect Dis 2007; 57: 443-446
217. True DG, Penmetcha M, Peckham SJ. Disseminated cryptococcal infection in rheumatoid arthritis treated with methotrexate and infliximab. J Rheumatol 2002; 29: 1561-1563
218. Lanternier F, Lortholary O. Liposomal amphotericin B: what is its role in 2008? Clin Microbiol Infect 2008; 14(Suppl 4): 71-83.
219. Velayos FS, Sandborn WJ. Pneumocystis carinii pneumonia during maintenance anti-tumor necrosis factor-alpha therapy with infliximab for Crohn's disease. Inflamm Bowel Dis 2004; 10: 657-660
220. Seddik M, Melliez H, Seguy D, Viget N, Cortot A, Colombel JF. Pneumocystis jiroveci (carinii) pneumonia after initiation of infliximab and azathioprine therapy in a patient with Crohn's disease. Inflamm Bowel Dis 2005; 11: 618-620
221. Josephson ME, Kristensen LH, Andersen VC. Pneumocystis jiroveci pneumonia during infliximab therapy. Ugeskr Laeger 2008; 170: 2159-2160
222. Estrada S, García-Campos F, Calderón R, Delgado E, Bengoa R, Enciso C. Pneumocystis jiroveci (carinii) pneumonia following a second infusion of infliximab in a patient with ulcerative colitis. Inflamm Bowel Dis 2009; 15: 315-316
223. Seddik M, Meliez H, Seguy D, Viget N, Cortot A, Colombel JF. Pneumocystis jiroveci (carinii) pneumonia following initiation of infliximab and azathioprine therapy in a patient with Crohn's disease. Inflam Bowel Dis 2004; 10: 436-437
224. Kaur N, Mahl TC. Pneumocystis jiroveci (carinii) pneumonia after infliximab therapy: a review of 84 cases. Dig Dis Sci 2007; 52: 1481-1484
225. Krajicek BJ, Thomas CF Jr, Limper AH. Pneumocystis pneumonia: current concepts in pathogenesis, diagnosis, and treatment. Clin Chest Med 2009; 30: 265-278
226. Popper DM, Scherl EJ. Prophylaxis against Pneumocystis pneumonia in patients with inflammatory bowel disease: toward a standard of care. Inflam Bowel Dis 2008; 14: 106-113
227. Green H, Paul M, Vidal L, Leibovici L. Prophylaxis of Pneumocystis pneumonia in immunocompromised non-HIV infected patients: systematic review and meta-analysis of randomised controlled trials. Mayo Clinic Proc 2007; 82: 1052-1059
228. Pareja JG, Garland R, Koziel H. Use of adjunctive corticosteroids in severe adult non-HIV Pneumocystis carinii pneumonia. Chest 1998; 113: 1215-1224
229. Filisetti D, Candolfi E. Immune response to Toxoplasma gondii. Ann Ist Super Sanita 2004; 40: 71-80.
230. Young JD, McGwire BS. Infliximab and reactivation of cerebral toxoplasmosis (response to letter). New Engl J Med 2005; 353: 1530-1531
231. Montoya JG. Liesenfeld O. Toxoplasmosis. Lancet 2004; 363: 1965-1976
232. Boatright MD, Wang BW. Clinical infection with Strongyloides stercoralis following etanercept use for rheumatoid arthritis. Arth Rheum 2005; 52: 1336-1337
233. Krishnamurthy R, Dincer EH, Whittemore D. Strongyloides stercoralis Hyperinfection in a patient with rheumatoid arthritis after Anti-TNF(alpha) therapy. JCR 2007; 13: 150-152
234. Stallmach A, Carstens O. Role of infections in the manifestation or reactivation of inflammatory bowel diseases. Inflamm Bowel Dis 2002; 8: 213-218
235. Gradel KO, Nielsen HL, Schønheyder HC, Ejlertsen T, Kristensen B, Nielsen H. Increased short- and long-term risk of inflammatory bowel disease after salmonella or campylobacter gastroenteritis. Gastroenterology 2009; 137: 495-501.
236. Geraghty EM, Ristow B, Gordon SM, Aronowitz P. Overwhelming parasitemia with Plasmodium falciparum infection in a patient receiving infliximab therapy for rheumatoid arthritis. Clin Infect Dis 2007; 44: e82-4.
237. National immunisation program CDP. Guide to vaccine contradictions and precautions. Accessed September 2009. http://www.cdc.gov/vaccines/recs/vacadmin/ downloads/contraindications-guide-508.pdf
238. National immunisation program CDP. Hepatitis A vaccination. Accessed September 2009. http://www.cdc.gov/vaccines/vpdvac/hepa/in-short-adult.htm#who
239. Günther M, Stark K, Neuhaus R, Reinke P, Schröder K, Bienzle U. Rapid decline of antibodies after hepatitis A immunisation in liver and renal transplant recipients. Transplantation 2001; 71: 477-479
240. DuPont HL, Capsuto EG. Persistent diarrhoea in travellers. Clin Infect Dis 1996; 22: 124-128
241. Adachi JA, Ericsson CD, Jiang ZD, Du Pont MW, Martinez-Sandoval F, Knirsch C, et al. Azithromycin found to be comparable to levofloxacin for the treatment of US travellers with acute diarrhoea acquired in Mexico. Clin Infect Dis 2003; 37: 1165-1171
242. Cobelens FG, van Deutekom H, Draayer-Jansen IW, Schepp-Beelen AC, van Gerven PJ, van Kessel RP, et al. Risk of infection with Mycobacterium tuberculosis in travellers to areas of high tuberculosis endemicity. Lancet 2000; 356: 461-465
243. Loutfy MR, Wilson M, Keystone JS, Kain KC. Serology and eosinophil count in the diagnosis and management of strongyloidiasis in a non-endemic area. Am J Trop Med Hyg 2002; 66: 749-752
244. Heijstek MW, Pileggi GC, Zonneveld-Huijssoon E, Armbrust W, Hoppenreijs EP, Uiterwaal CS, et al. Safety of measles, mumps and rubella vaccination in juvenile idiopathic arthritis. Annals of the rheumatic diseases 2007; 66: 1384-1387 (Pubitemid 47492487)
245. Khan S, Erlichman J, Rand EB. Live virus immunization after orthotopic liver transplantation. Pediatr Transplant 2006; 10: 78-82.
246. Fomin I, Caspi D, Levy V, Varsano N, Shalev Y, Paran D, et al. Vaccination against influenza in rheumatoid arthritis: the effects of disease modifying drugs, including TNF alpha blockers. Ann Rheum Dis 2006; 65: 191-194
247. Gelinck LB, van der Bijl AE, Beyer WE, Visser LG, Huizinga TW, van Hogezand RA, et al. The effect of anti-tumor necrosis factor alpha treatment on the antibody response to influenza vaccination. Ann Rheum Dis 2008; 67: 713-716
248. Kapetanovic MC, Saxne T, Nilsson JA. Influenza vaccination as model for testing immune modulation induced by anti-TNF and methotrexate therapy in rheumatoid arthritis patients. Rheumatology (Oxford) 2007; 46: 608-611
249. Kapetanovic MC, Saxne T, Sjöholm A, Truedsson L, Jönsson G, Geborek P. Influence of methotrexate, TNF blockers and prednisolone on antibody response to pneumococcal polysaccharide vaccine in patients with rheumatoid arthritis. Rheumatology (Oxford) 2006; 45: 106-111
250. Visvanathan S, Keenan GF, Baker DG, Levinson AI, Wagner CL. Response to pneumococcal vaccine in patients with early rheumatoid arthritis receiving infliximab plus methotrexate or methotrexate alone. J Rheumatol 2007; 34: 952-957
251. Chan AT, Cleeve V, Daymond TJ. Necrotising fasciitis in a patient receiving infliximab for rheumatoid arthritis. Postgrad Med J 2002; 78 (915): 47-48
252. Rahier JF, Yazdanpanah Y, Colombel JF, Travis SPL. The European (ECCO) Consensus on the prevention of opportunistic infections in IBD: What does it change for the clinician? Gut 2009; In press.